{"nctId":"NCT04074161","briefTitle":"Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity","startDateStruct":{"date":"2019-09-11","type":"ACTUAL"},"conditions":["Overweight","Obesity"],"count":338,"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo (semaglutide)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (semaglutide)"]},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide"]},{"label":"Placebo (liraglutide)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (liraglutide)"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Placebo (semaglutide)","otherNames":[]},{"name":"Liraglutide","otherNames":[]},{"name":"Placebo (liraglutide)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age 18 years or older at the time of signing informed consent\n* Body mass index (BMI) equal to or above 30.0 kg/m\\^2 or equal to or above 27.0 kg/m\\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* HbA1c equal to or above 48 mmol/mol (6.5%) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus\n* A self-reported change in body weight of more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg)","description":"Change from baseline (week 0) to week 68 in body weight (%) is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"10.5"},{"groupId":"OG001","value":"-6.4","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who From Baseline (Week 0) to Week 68 Achieved Body Weight Reduction Greater Than or Equal to (>=) 10% (Yes/no)","description":"Number of participants who achieved \\>= 10% weight reduction from baseline (week 0) to week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved \\>= 10% weight reduction, whereas 'No' infers the number of participants who did not achieve \\>= 10% weight reduction. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who From Baseline (Week 0) to Week 68 Achieved Body Weight Reduction >=15% (Yes/no)","description":"Number of participants who achieved \\>= 15% weight reduction from baseline (week 0) to week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved \\>= 15% weight reduction, whereas 'No' infers the number of participants who did not achieve \\>= 15% weight reduction. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who From Baseline (Week 0) to Week 68 Achieved Body Weight Reduction >=20% (Yes/no)","description":"Number of participants who achieved \\>= 20% weight reduction from baseline (week 0) to week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved \\>= 20% weight reduction, whereas 'No' infers the number of participants who did not achieve \\>= 20% weight reduction. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Waist Circumference","description":"Change from baseline (week 0) to week 68 in waist circumference is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"10.0"},{"groupId":"OG001","value":"-6.8","spread":"8.4"},{"groupId":"OG002","value":"-2.0","spread":"7.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Body Weight (Kilograms (kg))","description":"Change from baseline (week 0) to week 68 in body weight is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":"10.2"},{"groupId":"OG001","value":"-6.8","spread":"9.5"},{"groupId":"OG002","value":"-1.4","spread":"9.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Pooled Placebo and Liraglutide 3.0 mg Versus Pooled Placebo)","description":"Change from baseline (week 0) to week 68 in body weight (%) is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"10.5"},{"groupId":"OG001","value":"-6.4","spread":"7.7"},{"groupId":"OG002","value":"-1.6","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Systolic Blood Pressure","description":"Change from baseline (week 0) to week 68 in systolic blood pressure is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7","spread":"14"},{"groupId":"OG001","value":"-4","spread":"15"},{"groupId":"OG002","value":"5","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Diastolic Blood Pressure","description":"Change from baseline (week 0) to week 68 in diastolic blood pressure is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"9"},{"groupId":"OG001","value":"-1","spread":"11"},{"groupId":"OG002","value":"1","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Total Cholesterol (Milligram Per Deciliter (mg/dL)) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in total cholesterol (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"12.9"},{"groupId":"OG001","value":"1.00","spread":"15.0"},{"groupId":"OG002","value":"0.99","spread":"17.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Total Cholesterol (Millimoles Per Liter (mmol/L)) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in total cholesterol (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"12.9"},{"groupId":"OG001","value":"1.00","spread":"15.0"},{"groupId":"OG002","value":"0.99","spread":"17.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: High Density Lipoprotein (HDL) Cholesterol (mg/dL) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in HDL cholesterol (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"14.7"},{"groupId":"OG001","value":"1.02","spread":"14.4"},{"groupId":"OG002","value":"0.99","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: High Density Lipoprotein (HDL) Cholesterol (mmol/L) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in HDL cholesterol (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"14.7"},{"groupId":"OG001","value":"1.02","spread":"14.4"},{"groupId":"OG002","value":"0.99","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Low Density Lipoprotein (LDL) Cholesterol (mg/dL) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in LDL cholesterol (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"19.7"},{"groupId":"OG001","value":"1.01","spread":"23.4"},{"groupId":"OG002","value":"0.99","spread":"26.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Low Density Lipoprotein (LDL) Cholesterol (mmol/L) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in LDL cholesterol (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"19.7"},{"groupId":"OG001","value":"1.01","spread":"23.4"},{"groupId":"OG002","value":"0.99","spread":"26.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol (mg/dL) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in VLDL cholesterol (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"33.1"},{"groupId":"OG001","value":"0.89","spread":"36.9"},{"groupId":"OG002","value":"0.97","spread":"34.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in VLDL cholesterol (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"33.1"},{"groupId":"OG001","value":"0.89","spread":"36.9"},{"groupId":"OG002","value":"0.97","spread":"34.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Free Fatty Acids (FFA) (mg/dL) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in FFA (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"81.5"},{"groupId":"OG001","value":"0.87","spread":"77.7"},{"groupId":"OG002","value":"1.10","spread":"77.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Free Fatty Acids (FFA) (mmol/L) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in FFA (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"81.5"},{"groupId":"OG001","value":"0.87","spread":"77.7"},{"groupId":"OG002","value":"1.10","spread":"77.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Triglycerides (mg/dL) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in triglycerides (measured in mg/dL) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"33.0"},{"groupId":"OG001","value":"0.89","spread":"36.7"},{"groupId":"OG002","value":"0.98","spread":"35.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Lipids: Triglycerides (mmol/L) (Ratio to Baseline)","description":"Change from baseline (week 0) to week 68 in triglycerides (measured in mmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"33.0"},{"groupId":"OG001","value":"0.89","spread":"36.7"},{"groupId":"OG002","value":"0.98","spread":"35.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in High-sensitivity C-reactive Protein (Hs-CRP): Ratio to Baseline","description":"Change from baseline (week 0) to week 68 in hs-CRP (measured in mg/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"154.1"},{"groupId":"OG001","value":"0.73","spread":"93.0"},{"groupId":"OG002","value":"0.78","spread":"71.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Glycated Haemoglobin (HbA1c) (%)","description":"Change from baseline (week 0) to week 68 in HbA1c (%) is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.3"},{"groupId":"OG002","value":"0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Glycated Haemoglobin (HbA1c) (Millimoles Per Mole (mmol/Mol))","description":"Change from baseline (week 0) to week 68 in HbA1c is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"2.6"},{"groupId":"OG001","value":"-1.0","spread":"2.7"},{"groupId":"OG002","value":"1.2","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Fasting Plasma Glucose (mg/dL)","description":"Change from baseline (week 0) to week 68 in fasting plasma glucose is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"9.6"},{"groupId":"OG001","value":"-4.9","spread":"10.4"},{"groupId":"OG002","value":"2.4","spread":"10.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Fasting Plasma Glucose (mmol/L)","description":"Change from baseline (week 0) to week 68 in fasting plasma glucose is presented. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.5"},{"groupId":"OG001","value":"-0.3","spread":"0.6"},{"groupId":"OG002","value":"0.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Fasting Serum Insulin (Milli-international Units Per Liter (mIU/L)): Ratio to Baseline","description":"Change from baseline (week 0) to week 68 in fasting serum insulin (measured in mIU/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"57.3"},{"groupId":"OG001","value":"0.85","spread":"47.5"},{"groupId":"OG002","value":"0.98","spread":"56.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Week 0) to Week 68 in Fasting Serum Insulin (Picomoles Per Liter (Pmol/L)): Ratio to Baseline","description":"Change from baseline (week 0) to week 68 in fasting serum insulin (measured in pmol/L) is presented as ratio to baseline. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"57.3"},{"groupId":"OG001","value":"0.85","spread":"47.5"},{"groupId":"OG002","value":"0.98","spread":"56.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Baseline (Week 0) and Week 68 in Glycaemic Category (Normo-glycaemia, Pre-diabetes, Type 2 Diabetes (T2D))","description":"Number of participants in glycaemic categories, \"normo-glycaemia, pre-diabetes and type 2 diabetes\" at baseline (week 0) and 68 are presented. These categories were set as per the following criteria: 1) Normo-glycaemia: fasting plasma glucose (FPG) less than (\\<) 5.6 mmol/L (\\<100 mg/dL) and/or glycated haemoglobin (HbA1c) \\<5.7%; 2) Pre-diabetes: FPG 5.6 - 6.9 mmol/L (both inclusive), FPG 100 - 125 mg/dL (both inclusive) or HbA1c 5.7 - 6.4% (both inclusive); 3) Type 2 diabetes: FPG greater than or equal to (\\>=) 7.0 mmol/L (\\>=126 mg/dL) and/or HbA1c \\>=6.5%. Data is reported for 'in-trial' period: the uninterrupted time interval from date of randomization to date of last contact with trial site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who From Baseline (Week 0) to Week 68 Permanently Discontinued Randomized Trial Product","description":"Number of participants who from baseline (week 0) to week 68 permanently discontinued randomized trial product are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (TEAEs) From Baseline (Week 0) to Week 75","description":"An adverse event (AE) was any untoward medical occurrence in a clinical trial participant that was temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs mentioned here are TEAEs defined as AEs, with the onset of the event occurred in the on-treatment period. A time-point was considered on treatment if any dose of trial product has been administrated within the prior 49 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"904","spread":null},{"groupId":"OG001","value":"823","spread":null},{"groupId":"OG002","value":"522","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs) From Baseline (Week 0) to Week 75","description":"An AE was any untoward medical occurrence in a clinical trial participant that was temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as an AE that results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. SAEs occurred based on the on-treatment period is presented. A time-point was considered on treatment if any dose of trial product has been administrated within the prior 49 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":126},"commonTop":["Nausea","Constipation","Diarrhoea","Vomiting","Headache"]}}}